P2RX7 Modulators Overcome PD-L1 Resistance in Cancer Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for chronic inflammation and cancer often deregulate immune cell responses and are ineffective in patients with high PD-L1 expression or in reversing immunosuppression within the tumor microenvironment, leading to resistance to immunotherapy.
Innovation Solution
Development of P2RX7 modulators that potentiate the action of P2RX7 receptors in the presence of extracellular ATP, enhancing anti-tumor T cell responses, increasing tumor immunogenicity, and reducing immunosuppressive cell infiltration in the tumor microenvironment.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing treatments are used against chronic inflammation or cancer, then immune cell response is deregulated, but treatment effectiveness is reduced and resistance develops
Solution Approach 1:
The patent changes the pharmacological parameter from immune checkpoint inhibition to P2RX7 receptor modulation. By targeting a different receptor pathway (P2RX7 instead of PD-1/PD-L1 or CTLA-4), the treatment achieves therapeutic effect without the harmful deregulation of immune cell responses that characterizes existing immunotherapies
Solution Approach 2:
The P2RX7 modulator acts as an intermediary substance that restores proper immune cell function. Rather than directly inhibiting immune checkpoints, the modulator works through P2RX7 receptor signaling to indirectly restore immune cell response regulation, thereby reducing harmful deregulation while maintaining treatment effectiveness
2Reliability
If immunotherapies are used to reverse immune checkpoints, then T cell responses are amplified, but patients with high PD-L1 expression remain resistant
Solution Approach 1:
Instead of inhibiting immune checkpoints (the conventional approach), the patent inverts the strategy by modulating P2RX7 receptors to restore immune cell function. This alternative pathway bypasses the PD-L1 resistance mechanism, enabling T cell response amplification even in patients with high PD-L1 expression
Solution Approach 2:
The P2RX7 modulator provides a universal therapeutic approach that works across different patient subgroups. By targeting P2RX7 rather than PD-L1, the treatment overcomes the limitation of PD-L1 expression heterogeneity and provides consistent anti-tumor efficacy regardless of baseline PD-L1 levels
3Reliability
If immunotherapies are used to amplify T cell responses, then immunosuppression within tumor microenvironment is decreased, but myeloid-derived suppressor cells continue to blunt T lymphocyte activity
Solution Approach 1:
The P2RX7 modulator serves as an intermediary that restores T cell function without directly addressing MDSC-mediated suppression. By modulating P2RX7 signaling, the treatment indirectly counteracts immunosuppression effects, allowing T cells to regain anti-tumor activity despite the presence of MDSC in the tumor microenvironment
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The P2RX7 modulators effectively treat both inflammatory diseases and cancer by restoring functional anti-tumor T cell responses and reducing clinical signs of inflammation, offering a new approach to overcome treatment resistance.
Implementation Method 1
Purinergic receptors from the P2X family are ATP-gated-cation channels formed by three protein monomers. Among the seven receptor members, receptor P2X7 (encoded by gene P2RX7) is the only one having the potential to mediate large pore formation and ultimately cell death in a microenvironment rich of extracellular ATP.
Implementation Method 2
The present invention concerns compounds of formula (I), their enantiomers and their pharmaceutically acceptable salts, and their use in therapy, particularly for the prevention and/or treatment of cancer or inflammatory diseases.
Implementation Method 3
the inventors further discovered that said compounds act both directly on tumor cells by increasing tumor immunogenicity, as well as on tumor microenvironment by decreasing infiltration of immunosuppressive cells
Data Source
AI summary
The present invention relates to compounds of formula (I), their enantiomers and their pharmaceutically acceptable salts, and their use in therapy, particularly for the treatment of cancer or inflammatory diseases.